Antihistamines and driving ability: evidence from on-the-road driving studies during normal traffic.

BACKGROUND All antihistamines are capable of crossing the blood-brain barrier and thus may cause sedation. Most antihistamine users are ambulatory patients and therefore presumably drive a car. OBJECTIVE To summarize the effects of antihistamine drugs on driving ability. DATA SOURCES AND STUDY SELECTION A literature search (MEDLINE and cross-references) was performed using the keywords driving and antihistamine. Sixteen studies using the on-the-road driving test during normal traffic were included in the review. Studies were double-blind and placebo-controlled and included a positive control. RESULTS First-generation antihistamines (diphenhydramine, triprolidine, terfenadine, dexchlorpheniramine, clemastine) significantly impair driving performance after both one-time and repeated (daily) administration. Second-generation antihistamines (cetirizine, loratadine, ebastine, mizolastine, acrivastine, emedastine, mequitazine) may also impair driving performance, but the magnitude and extent of impairment depend on the administered dose, sex, and time between testing and treatment administration. Tolerance develops after 4 to 5 days of administration, but impairment is not absent. Third-generation antihistamines (fexofenadine and levocetirizine) have been shown to produce no driving impairment after both one-time and repeated administration. CONCLUSIONS First- and second-generation antihistamines may significantly impair driving performance. In the context of driving safety but also taking into account the cardiotoxic properties of some of the second-generation antihistamines, we advise treating patients with third-generation antihistamines such as fexofenadine and levocetirizine.

[1]  E. Volkerts,et al.  A comparative study of on‐the‐road and simulated driving performance after nocturnal treatment with lormetazepam 1 mg and oxazepam 50 mg , 1992 .

[2]  J. O'hanlon,et al.  Fexofenadine's effects, alone and with alcohol, on actual driving and psychomotor performance. , 1998, The Journal of allergy and clinical immunology.

[3]  M. Verbaten,et al.  Acute and subchronic effects of levocetirizine and diphenhydramine on memory functioning, psychomotor performance, and mood. , 2003, The Journal of allergy and clinical immunology.

[4]  J. Ramaekers,et al.  Effects of emedastine and cetirizine, alone and with alcohol, on actual driving of males and females , 2002, Journal of psychopharmacology.

[5]  I. Hindmarch.  CNS effects of antihistamines: is there a third generation of non-sedative drugs? , 2002 .

[6]  V Starbuck,et al.  Initial and steady-state effects of diphenhydramine and loratadine on sedation, cognition, mood, and psychomotor performance. , 1997, Archives of internal medicine.

[7]  John R Bloomfield,et al.  Effects of Fexofenadine, Diphenhydramine, and Alcohol on Driving Performance , 2000, Annals of Internal Medicine.

[8]  M. Burns,et al.  Effects of terfenadine, diphenhydramine, and placebo on skills performance. , 1988, Cutis.

[9]  Rob Wallis,et al.  Corrigendum to “Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development” [Cardiovasc. Res. 58 (2003) 32–45] , 2004 .

[10]  F. Gengo,et al.  Quantitative effects of cetirizine and diphenhydramine on mental performance measured using an automobile driving simulator. , 1990, Annals of allergy.

[11]  J. O'hanlon,et al.  Driving performance under the influence of drugs: rationale for, and application of, a new test. , 1984, British journal of clinical pharmacology.

[12]  M. Mattila,et al.  Acute and subacute actions on human performance and interactions with diazepam of temelastine (SK & F 93944) and diphenhydramine , 2004, European Journal of Clinical Pharmacology.

[13]  M Malik,et al.  Problems of Heart Rate Correction in Assessment of Drug‐Induced QT Interval Prolongation , 2001, Journal of cardiovascular electrophysiology.

[14]  A. Camm,et al.  Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. , 2003, Cardiovascular research.

[15]  E. Volkerts,et al.  Does cetirizine belong to the new generation of antihistamines? An investigation into its acute and subchronic effects on highway driving, psychometric test performance and daytime sleepiness , 1992 .

[16]  Roberts Dj.  Assessing the cardiac safety of ebastine. Epilogue. , 1999 .

[17]  J. Bousquet,et al.  Allergic rhinitis and its impact on asthma. , 2001, The Journal of allergy and clinical immunology.

[18]  Joris C Verster,et al.  Residual Effects of Middle-of-the-Night Administration of Zaleplon and Zolpidem on Driving Ability, Memory Functions, and Psychomotor Performance , 2002, Journal of clinical psychopharmacology.

[19]  T. Haahtela,et al.  No effect of oral treatment with an intestinal bacterial strain, Lactobacillus rhamnosus (ATCC 53103), on birch‐pollen allergy: a placebo‐controlled double‐blind study , 2002, Allergy.

[20]  H. L. Snyder,et al.  The effects of Benadryl and Hismanal on psychomotor performance and perceived performance. , 1993, Aviation, space, and environmental medicine.

[21]  A. Egberts,et al.  Limited adherence to safety instructions in drug leaflets. , 2002, British journal of clinical pharmacology.

[22]  J. Ramaekers.  Antidepressants and driver impairment: empirical evidence from a standard on-the-road test. , 2003, The Journal of clinical psychiatry.

[23]  L. Trupin,et al.  The work impact of asthma and rhinitis: findings from a population-based survey. , 2001, Journal of clinical epidemiology.

[24]  J F O'Hanlon,et al.  Diazepam impairs lateral position control in highway driving. , 1982, Science.

[25]  L. Annunziato,et al.  Cardiotoxic potential and CNS effects of first-generation antihistamines. , 2000, Trends in pharmacological sciences.

[26]  I. Hindmarch,et al.  A double-blind, placebo-controlled investigation of the effects of fexofenadine, loratadine and promethazine on cognitive and psychomotor function. , 1999, British journal of clinical pharmacology.

[27]  J. F. O'Hanlon,et al.  Effects of loratadine and cetirizine on actual driving and psychometric test performance, and EEG during driving , 2004, European Journal of Clinical Pharmacology.

[28]  A. Vermeeren,et al.  Residual effects on actual car driving of evening dosing of chlorpheniramine 8 and 12 mg when used with terfenadine 60 mg in the morning , 1998 .

[29]  M. Verbaten,et al.  Driving ability after acute and sub-chronic administration of levocetirizine and diphenhydramine: a randomized, double-blind, placebo-controlled trial , 2003, Psychopharmacology.

[30]  D De Waard,et al.  Acute and subchronic effects of the H1-histamine receptor antagonist ebastine in 10, 20 and 30 mg dose, and triprolidine 10 mg on car driving performance. , 1993, British journal of clinical pharmacology.

[31]  G. Rhodes,et al.  Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects. , 2005, British journal of clinical pharmacology.

[32]  A. Moss,et al.  A review of the cardiac systemic side‐effects of antihistamines: ebastine , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[33]  F. Gengo,et al.  Antihistamines, drowsiness, and psychomotor impairment: central nervous system effect of cetirizine. , 1987, Annals of allergy.

[34]  J. Gras,et al.  Effects of H1 Antihistamines on Animal Models of QTc Prolongation , 1999, Drug safety.

[35]  J F O'Hanlon,et al.  Antihistamine effects on actual driving performance in a standard test: a summary of Dutch experience, 1989‐94 , 1995, Allergy.

[36]  P. Marshall,et al.  Effects of allergy season on mood and cognitive function. , 1993, Annals of allergy.

[37]  J F O'Hanlon,et al.  Venlafaxine's effects on healthy volunteers' driving, psychomotor, and vigilance performance during 15-day fixed and incremental dosing regimens. , 1998, Journal of clinical psychopharmacology.

[38]  J. Morganroth,et al.  Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval. , 2001, British journal of clinical pharmacology.

[39]  D. Malone,et al.  A cost of illness study of allergic rhinitis in the United States. , 1997, The Journal of allergy and clinical immunology.

[40]  A. Moss,et al.  Cardiac Effects of Ebastine and Other Antihistamines in Humans , 1999, Drug safety.

[41]  M. Malik.  Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval. , 2002, British journal of clinical pharmacology.

[42]  F. Gengo,et al.  The pharmacodynamics of diphenhydramine‐induced drowsiness and changes in mental performance , 1989, Clinical pharmacology and therapeutics.